Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Crucell N.V. (CRXL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (13)	5/30/2001 6:44:50 PM
From: aknahow	Respond to of 560

About 13 companies involved in phage antibody - display are looking at licensing agreements with XOMA. 6 appear close to signing agreements. The CEO stated that many of them will have to come to an agreement if they want to continue doing what they have been doing. He mentioned that for the majority, an agreement, does not seem to be a problem. These agreements include up front payments, milestones and small royalities. (I have included this last part as he did not once again re cover the terms, this has been done in the past and is in their p.r. releases). One can listen to the entire annual meeting if one wants to. Link at xoma web site. But simply reporting on the phage comments. Let me admit, I have little understanding of phages, nor the size of the markets involved.